Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Fineline Cube May 8, 2026
Company Drug

Roche’s Cosentyx 300mg Dosage Approved by NMPA for Ankylosing Spondylitis Treatment

Fineline Cube Apr 3, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Changzhou Qianhong Bio-pharma Receives NMPA Approval for QHRD107 Phase II AML Study

Fineline Cube Apr 3, 2023

China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced obtaining approval from the National...

Company Drug

Konruns Pharmaceutical Reports Positive Efficacy Results for KC1036 in Advanced ESCC

Fineline Cube Apr 3, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the publication of efficacy study results...

Company Deals

Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation

Fineline Cube Apr 3, 2023

The Boao Lecheng Medical Tourism Pilot Zone in Hainan Province has announced a strategic partnership...

Company Drug

Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis

Fineline Cube Apr 3, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a...

Company Drug

Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012

Fineline Cube Apr 3, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan...

Company

Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization

Fineline Cube Apr 3, 2023

China-based Henlius (HKG: 2696) has announced its annual results for 2022, revealing that revenues reached...

Company

Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates

Fineline Cube Mar 31, 2023

China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key...

Company Deals Digital

ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector

Fineline Cube Mar 31, 2023

Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has...

Company Deals

Pharmaron Secures UK Government Grant to Expand Viral Vector Manufacturing Facility

Fineline Cube Mar 31, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...

Company Drug

HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC

Fineline Cube Mar 31, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling...

Company Deals

Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’

Fineline Cube Mar 31, 2023

Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the...

Company Drug

Huadong Medicine Wins NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Mar 31, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...

Company Deals

Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership

Fineline Cube Mar 31, 2023

Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide...

Company Drug

Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH

Fineline Cube Mar 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...

Company Drug

Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502

Fineline Cube Mar 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...

Company Deals

Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration

Fineline Cube Mar 31, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment

Fineline Cube Mar 31, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology...

Medical Device

IceCure Medical Gains NMPA Approval for Cryoablation Technology in China

Fineline Cube Mar 31, 2023

Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s...

Company Deals

SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal

Fineline Cube Mar 31, 2023

China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research...

Posts pagination

1 … 538 539 540 … 661

Recent updates

  • Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment
  • Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential
  • Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy
  • Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment
  • China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Company Drug

Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy

Company Drug

Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.